Pentraxin-3: A New Parameter in Predicting the Severity of Diabetic Foot Infection?

Overview

Journal Int Wound J

Specialties Emergency Medicine
Orthopedics

Date 2019 Feb 16

PMID 30767386

Citations 6

Authors

Safak Ozer Balin

Ayse Sagmak Tartar

Kader Ugur

Faruk Kilinc

Selda Telo

Ali Bal

Mehmet Balin

Ayhan Akbulut

Affiliations

Soon will be listed here.

Abstract

This study was undertaken to evaluate the diagnostic and prognostic values of pentraxin-3 (PTX-3) in patients with infected diabetic foot ulcers (IDFU) as well as to assess the association between PTX-3 levels and IDFU severity. This study included 60 IDFU patients (Group 1), 45 diabetic patients without DFU (Group 2), and 45 healthy controls. Patients with IDFU were divided into mild, moderate, and severe subgroups based on classification of clinical severity. Patients who underwent amputation were also documented. Blood samples were collected to determine PTX-3 levels. PTX-3 levels in healthy controls, Group 1, and Group 2 were 5.83 (3.41-20) ng/mL, 1.47 (0.61-15.13) ng/mL, and 3.26 (0.67-20) ng/mL, respectively. A negative correlation between plasma PTX-3 and glucose levels was found. There were significant differences in terms of procalcitonin (PCT) and PTX-3 levels in the subgroup analysis of Group 1. The PTX-3 level in patients who did or did not undergo amputation was 4.1 (0.8-13.7) and 1 (0.6-15.1) ng/mL, respectively. Results suggest that PTX-3 is a particularly effective marker in patients with IDFU, both in terms of predicting disease severity and assisting in the decision to perform amputation.

Citing Articles

Pentraxin-3 and Other Inflammatory Markers for an Infected Diabetic Foot Ulcer Diagnosis: A Prospective Study.

Ardelean A, Balta D, Neamtu C, Neamtu A, Rosu M, Pilat L Diagnostics (Basel). 2023; 13(14).

PMID: 37510110 PMC: 10377911. DOI: 10.3390/diagnostics13142366.

Classification Model for Diabetic Foot, Necrotizing Fasciitis, and Osteomyelitis.

Kim J, Yoo G, Lee T, Kim J, Seo D, Kim J Biology (Basel). 2022; 11(9).

PMID: 36138789 PMC: 9495746. DOI: 10.3390/biology11091310.

Diabetic Wound-Healing Science.

Burgess J, Wyant W, Abujamra B, Kirsner R, Jozic I Medicina (Kaunas). 2021; 57(10).

PMID: 34684109 PMC: 8539411. DOI: 10.3390/medicina57101072.

Guidelines on multidisciplinary approaches for the prevention and management of diabetic foot disease (2020 edition).

Wang A, Lv G, Cheng X, Ma X, Wang W, Gui J Burns Trauma. 2020; 8:tkaa017.

PMID: 32685563 PMC: 7336185. DOI: 10.1093/burnst/tkaa017.

Serum pentraxin-3 follows a logarithmic distribution particularly at low expected levels.

Ilgen U, Yayla M, Gokalp C, Emmungil H, Duzgun N Int Wound J. 2019; 16(6):1572-1574.

PMID: 31418522 PMC: 7949185. DOI: 10.1111/iwj.13184.

References

Lavery L, Armstrong D, Wunderlich R, Mohler M, Wendel C, Lipsky B . Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006; 29(6):1288-93. DOI: 10.2337/dc05-2425. View

Kao S, Yang H, Tsao S, Cheng C, Bien M, Yu M . Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia. Clin Chem Lab Med. 2012; 51(4):907-13. DOI: 10.1515/cclm-2012-0459. View

Aragon-Sanchez J . Seminar review: A review of the basis of surgical treatment of diabetic foot infections. Int J Low Extrem Wounds. 2011; 10(1):33-65. DOI: 10.1177/1534734611400259. View

Armstrong D, Wrobel J, Robbins J . Guest Editorial: are diabetes-related wounds and amputations worse than cancer?. Int Wound J. 2007; 4(4):286-7. DOI: 10.1111/j.1742-481X.2007.00392.x. View

Osorio-Conles O, Guitart M, Chacon M, Maymo-Masip E, Moreno-Navarrete J, Montori-Grau M . Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab. 2011; 301(6):E1254-61. DOI: 10.1152/ajpendo.00163.2011. View

Liu S, Qu X, Liu F, Wang C . Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Mediators Inflamm. 2014; 2014:421429. PMC: 4235333. DOI: 10.1155/2014/421429. View

Saltoglu N, Yemisen M, Ergonul O, Kadanali A, Karagoz G, Batirel A . Predictors for limb loss among patient with diabetic foot infections: an observational retrospective multicentric study in Turkey. Clin Microbiol Infect. 2015; 21(7):659-64. DOI: 10.1016/j.cmi.2015.03.018. View

Azzurri A, Sow O, Amedei A, Bah B, Diallo S, Peri G . IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005; 7(1):1-8. DOI: 10.1016/j.micinf.2004.09.004. View

Jafari N, Safaee Firouzabadi M, Izadi M, Safaee Firouzabadi M, Saburi A . Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers?. Int J Endocrinol Metab. 2014; 12(1):e13376. PMC: 3968998. DOI: 10.5812/ijem.13376. View

10.

Ogurtsova K, da Rocha Fernandes J, Huang Y, Linnenkamp U, Guariguata L, Cho N . IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017; 128:40-50. DOI: 10.1016/j.diabres.2017.03.024. View

11.

Cavanagh P, Lipsky B, Bradbury A, Botek G . Treatment for diabetic foot ulcers. Lancet. 2005; 366(9498):1725-35. DOI: 10.1016/S0140-6736(05)67699-4. View

12.

Doni A, Michela M, Bottazzi B, Peri G, Valentino S, Polentarutti N . Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J Leukoc Biol. 2006; 79(4):797-802. DOI: 10.1189/jlb.0905493. View

13.

Pecoraro R, Reiber G, BURGESS E . Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990; 13(5):513-21. DOI: 10.2337/diacare.13.5.513. View

14.

Reiner M, Khoury W, Canales M, Chmielewski R, Patel K, Razzante M . Procalcitonin as a Biomarker for Predicting Amputation Level in Lower Extremity Infections. J Foot Ankle Surg. 2017; 56(3):484-491. DOI: 10.1053/j.jfas.2017.01.014. View

15.

Armstrong D, Fiorito J, Leykum B, Mills J . Clinical efficacy of the pan metatarsal head resection as a curative procedure in patients with diabetes mellitus and neuropathic forefoot wounds. Foot Ankle Spec. 2012; 5(4):235-40. DOI: 10.1177/1938640012449038. View

16.

Karakas A, Arslan E, Cakmak T, Aydin I, Akgul E, Demirbas S . Predictive Value of Soluble CD14, Interleukin-6 and Procalcitonin For Lower Extremity Amputation in People with Diabetes with Foot Ulcers: A Pilot Study. Pak J Med Sci. 2014; 30(3):578-82. PMC: 4048510. DOI: 10.12669/pjms.303.4575. View

17.

Inoue K, Kodama T, Daida H . Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med. 2012; 2012:657025. PMC: 3278926. DOI: 10.1155/2012/657025. View

18.

Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B . Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001; 29(7):1404-7. DOI: 10.1097/00003246-200107000-00017. View

19.

Inforzato A, Reading P, Barbati E, Bottazzi B, Garlanda C, Mantovani A . The "sweet" side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation. Front Immunol. 2013; 3:407. PMC: 3539679. DOI: 10.3389/fimmu.2012.00407. View

20.

Mayfield J, Reiber G, Maynard C, Czerniecki J, Sangeorzan B . The epidemiology of lower-extremity disease in veterans with diabetes. Diabetes Care. 2004; 27 Suppl 2:B39-44. DOI: 10.2337/diacare.27.suppl_2.b39. View